|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS seems to be directly associated with type I EC, and most studies support its early involvement in carcinogenesis.
|
30711927 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations were identified in 14 PPEs and 1 concurrent endometrial carcinoma.
|
31079233 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Endometrial cancers are associated with several critical gene mutations, including PIK3A, PTEN, and KRAS.
|
30765787 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ninty-eight of 570 endometrial carcinomas (17%) harbored canonical KRAS mutations.
|
30489318 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
K-Ras mutations were observed in 12.1% of AH, and in 19.6% of EC cases.
|
30430425 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MEK inhibition may be a promising treatment modality, not just for ECs with mutated KRAS, but also for those with retained PTEN.
|
29426295 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations seemed to be more common in sporadic MSI ECs than in LS-related ECs even if further studies are needed to confirm this finding.
|
30420047 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent with these effects, G01 selectively inhibited the proliferation of KRAS-transformed pancreatic, colon, and endometrial cancer cells.
|
29970615 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In our previous study, mucinous endometrial carcinomas were associated with a significantly higher frequency of KRAS mutations as compared with matched conventional endometrioid carcinomas.
|
29303928 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations.
|
29067643 |
2017 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumor suppressor gene TP53 is mutated exclusively with the HYDIN, KRAS, and PTEN genes in large intestine, lung, and endometrial cancers respectively, indicating that TP53 takes part in different signaling pathways in different cancers.
|
26212640 |
2015 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Information on these various genetic changes has been primarily derived from studying groups of either hyperplasias or cancers.We evaluated both hyperplastic and EC tissue obtained from the same surgical specimens for KRAS mutations, microsatellite instability (MSI), and mismatch repair gene methylation, and results were correlated between the paired hyperplastic tissue and EC.
|
25768080 |
2015 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
|
24811063 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Possible carcinogenic mechanisms include imbalance between endometrial proliferation by unopposed estrogen and the mismatch repair (MMR) system; hypermethylation of the MMR gene hMLH1; mutation of PTEN, β-catenin and K-ras genes in type I endometrial cancer and of HER-2/neu and p53 genes in type II endometrial cancer; hypermethylation of SPRY2, RASSF1A, RSK4, CHFR and CDH1; and methylation of tumor suppressor microRNAs, including miR-124, miR-126, miR-137, miR-491, miR-129-2 and miR-152.
|
25131761 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The KRAS-variant may be a genetic marker of risk for type 2 endometrial cancers.
|
24732316 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the expression of ARID1A in 146 endometrial cancers (130 EECs and 16 non-EECs) in relation to alterations in the PI3K-Akt pathway (PTEN expression/KRAS/PIK3CA mutations), TP53 status (TP53 immunohistochemistry) and microsatellite instability.
|
23702729 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated that side-population (SP) cells in human endometrial cancer cells (Hec1 cells) and in rat endometrial cells expressing oncogenic human K-Ras protein (RK12V cells) have features of cancer stem cells (CSCs).
|
23500085 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no significant difference noted with regard to the frequency of KRAS mutations in cases of sporadic EC (10.3%) compared with LS-associated EC (3.4%).
|
23760948 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
|
24077915 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Endometrioid endometrial cancers (EEC) frequently harbor coexisting mutations in phosphoinositide 3-kinase (PI3K) pathway genes, including PTEN, PIK3CA, PIK3R1, and KRAS.
|
23674493 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that mutational statuses of PTEN and K-Ras might be useful predictors of sensitivity to NVP-BEZ235 in certain endometrial carcinomas.
|
22662154 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study was aimed at analyzing alterations in K-ras gene and SMAD4 gene promoter in endometrial carcinoma tissue in Serbian patients.
|
22266936 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results emphasize the potential for targeting FGFR2, KRAS and PIK3CA mutations in endometrial cancer for development of novel therapeutic strategies.
|
23300780 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in KRAS and BRAF genes are not directly implicated in the development of a MELF pattern of invasion in endometrial carcinoma.
|
20591910 |
2010 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we isolated and characterized the SP cells in human endometrial cancer cells and in rat endometrial cells expressing oncogenic human K-Ras protein.
|
20008133 |
2010 |